舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的观察(1)
摘要：目的 观察舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的临床效果。方法 选取2017年6月～2018年12月在我院诊治的88例脑卒中后抑郁患者，随机分为对照组和观察组，各44例。对照组采用舒肝解郁胶囊治疗，观察组在对照组治疗的基础上加用西酞普兰治疗，比较两组治疗后HAMD评分、神经功能缺损评分、生活能力改善以及不良反应发生情况。结果 观察组治疗后HAMD评分为(10.13±2.18)分、神经功能缺损评分为(9.72±3.21)分，均低于对照组的(16.72±2.42)分、(13.02±3.13)分，差异有统计学意义(P<0.05);观察组患者生活能力改善率(72.72%)优于对照组(45.45%)，差异有统计学意义(P<0.05);两组治疗期间均未发生明显不良反应。结论 舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁效果确切，有助于提高患者生活能力，改善神经功能缺损，其临床治疗效果优于单纯采用舒肝解郁胶囊治疗效果，且较安全。
关键词：舒肝解郁胶囊;西酞普兰;脑卒中;抑郁
, http://www.100md.com
Abstract：Objective To observe the clinical effect of Shugan Jieyu Capsule combined with citalopram in the treatment of post-stroke depression. Methods 88 patients with post-stroke depression who were treated in our hospital from June 2017 to December 2018 were randomly divided into control group and observation group， 44 cases each. The control group was treated with Shugan Jieyu Capsule. The observation group was treated with citalopram on the basis of the control group. The HAMD score， neurological deficit score， improvement of living ability and adverse reactions were compared between the two groups.Results The HAMD score of the observation group was (10.13±2.18) and the neurological deficit score was (9.72±3.21)， which was lower than that of the control group (16.72±2.42) and (13.02±3.13)，the difference was statistically significant(P<0.05); the improvement rate of life ability of the observation group (72.72%) was better than that of the control group (45.45%)， the difference was statistically significant (P<0.05); no significant adverse reactions occurred during the treatment period.Conclusion Shugan Jieyu Capsule combined with citalopram is effective in treating post-stroke depression， which can improve the patient's ability to live and improve neurological deficit. The clinical treatment effect is better than that of Shugan Jieyu Capsule， and it is safer.
, 百拇医药
Key words：Shugan Jieyu Capsule;Citalopram;Stroke;Depression
脑卒中(stroke)是由于脑部血液供应不足或障碍，引起大脑组织处于缺血、缺氧状态，造成大脑组织局部坏死或软化，出现相应的体征和神经系统症状[1]。目前，我国脑卒中发病率逐年增高，其致死率、死亡率较高，研究显示脑卒中后抑郁患者病死率高，患者主要表现为情绪低落、兴趣丧失、睡眠障碍等。抑郁的发生不仅会延缓患者神经功能的恢复，严重威胁患者的生命健康。脑卒中发病较快，治疗周期长，预后效果不佳，其中抑郁是最为常见，称之为脑卒中后抑郁，对患者的生活质量和健康造成严重的影响，甚至会导致患者死亡。随着临床对该疾病的不断深入研究，采用中成药治疗脑卒中后抑郁具有显著的优势。本研究结合2017年6月～2018年12月在我院诊治的88例脑卒中后抑郁患者临床资料，分析舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的效果，现报告如下。
1资料与方法
, 百拇医药
1.1一般资料 选取2017年6月～2018年12月在天津市静海区医院诊治的88例脑卒中后抑郁患者为研究对象，将其随机分为对照组和观察组，每组44例。纳入标準：①均符合第四届全国脑血管病会议制定的脑梗死诊断标准;②符合《中符合国精神疾病诊断与分类标准第二版修订本》中关于抑郁症的诊断;③抑郁发病在脑卒中之后;④所有受试者神志清楚，生命体征稳定。排除标准：①合并有心、肝、肾等严重系统疾病者;②双相情感性精神障碍抑郁相者，或非抑郁性精神病者、老年性痴呆、癫痫以及其他精神性疾患;③拒绝服药(不愿服中药)及有严重自杀倾向者;④对本文研究药物过敏者。对照组男性23例，女性21例;年龄45～68岁，平均年龄(51.67±4.12)岁，病程2～6个月，平均病程(3.52±1.51)个月。观察组男性24例，女性20例;年龄50～70岁，平均年龄(55.17±6.45)岁，病程2～8个月，平均病程(4.51±1.51)个月。两组年龄、性别、病程比较，差异无统计学意义(P>0.05)，具有可比性。本研究经医院伦理委员会批准，所有患者均自愿参加本研究，并签署知情同意书。, 百拇医药(朱鸣峰)
关键词：舒肝解郁胶囊;西酞普兰;脑卒中;抑郁
, http://www.100md.com
Abstract：Objective To observe the clinical effect of Shugan Jieyu Capsule combined with citalopram in the treatment of post-stroke depression. Methods 88 patients with post-stroke depression who were treated in our hospital from June 2017 to December 2018 were randomly divided into control group and observation group， 44 cases each. The control group was treated with Shugan Jieyu Capsule. The observation group was treated with citalopram on the basis of the control group. The HAMD score， neurological deficit score， improvement of living ability and adverse reactions were compared between the two groups.Results The HAMD score of the observation group was (10.13±2.18) and the neurological deficit score was (9.72±3.21)， which was lower than that of the control group (16.72±2.42) and (13.02±3.13)，the difference was statistically significant(P<0.05); the improvement rate of life ability of the observation group (72.72%) was better than that of the control group (45.45%)， the difference was statistically significant (P<0.05); no significant adverse reactions occurred during the treatment period.Conclusion Shugan Jieyu Capsule combined with citalopram is effective in treating post-stroke depression， which can improve the patient's ability to live and improve neurological deficit. The clinical treatment effect is better than that of Shugan Jieyu Capsule， and it is safer.
, 百拇医药
Key words：Shugan Jieyu Capsule;Citalopram;Stroke;Depression
脑卒中(stroke)是由于脑部血液供应不足或障碍，引起大脑组织处于缺血、缺氧状态，造成大脑组织局部坏死或软化，出现相应的体征和神经系统症状[1]。目前，我国脑卒中发病率逐年增高，其致死率、死亡率较高，研究显示脑卒中后抑郁患者病死率高，患者主要表现为情绪低落、兴趣丧失、睡眠障碍等。抑郁的发生不仅会延缓患者神经功能的恢复，严重威胁患者的生命健康。脑卒中发病较快，治疗周期长，预后效果不佳，其中抑郁是最为常见，称之为脑卒中后抑郁，对患者的生活质量和健康造成严重的影响，甚至会导致患者死亡。随着临床对该疾病的不断深入研究，采用中成药治疗脑卒中后抑郁具有显著的优势。本研究结合2017年6月～2018年12月在我院诊治的88例脑卒中后抑郁患者临床资料，分析舒肝解郁胶囊联合西酞普兰治疗脑卒中后抑郁的效果，现报告如下。
1资料与方法
, 百拇医药
1.1一般资料 选取2017年6月～2018年12月在天津市静海区医院诊治的88例脑卒中后抑郁患者为研究对象，将其随机分为对照组和观察组，每组44例。纳入标準：①均符合第四届全国脑血管病会议制定的脑梗死诊断标准;②符合《中符合国精神疾病诊断与分类标准第二版修订本》中关于抑郁症的诊断;③抑郁发病在脑卒中之后;④所有受试者神志清楚，生命体征稳定。排除标准：①合并有心、肝、肾等严重系统疾病者;②双相情感性精神障碍抑郁相者，或非抑郁性精神病者、老年性痴呆、癫痫以及其他精神性疾患;③拒绝服药(不愿服中药)及有严重自杀倾向者;④对本文研究药物过敏者。对照组男性23例，女性21例;年龄45～68岁，平均年龄(51.67±4.12)岁，病程2～6个月，平均病程(3.52±1.51)个月。观察组男性24例，女性20例;年龄50～70岁，平均年龄(55.17±6.45)岁，病程2～8个月，平均病程(4.51±1.51)个月。两组年龄、性别、病程比较，差异无统计学意义(P>0.05)，具有可比性。本研究经医院伦理委员会批准，所有患者均自愿参加本研究，并签署知情同意书。, 百拇医药(朱鸣峰)